Similarly, metformin, a frontline medication for type 2 diabetes, effectively prevents the activation of the TXNIP/NLRP-3 inflammasome by mitigating ER stress and activating AMPK in macrophages. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.